Approaching Monday (Sept. 17th 2007) Trading Session

I've been in cash for a while (after liquidating my trades last Thursday).

This Monday, I will be conservative in my stock selections.

I've generated a watch list of stocks that I could be trading on Monday.

These stocks include: CVGW, VRTX, & BIIB.

Below excerpts taken from Google finance:

Calavo Growers, Inc. (Calavo) is engaged in the procurement and marketing of avocados and other perishable foods, and the preparation and distribution of processed avocado products. Through Calavo's three operating facilities in Southern California, distribution centers in Texas and New Jersey, and two facilities in Mexico, the Company sorts, packs and/or ripens avocados procured in California and Mexico, and prepares processed avocado products. In addition, the Company procures avocados internationally, principally from Chile and the Dominican Republic, and distributes other perishable foods, such as Hawaiian-grown papayas. During fiscal 2006, it operated in two business segments: fresh products and processed products. In August 2006, the Company entered into a joint venture agreement with San Rafael Distributing (SRD), under the name of Maui Fresh International, LLC (Maui Fresh), for the purpose of the marketing, sale and distribution of fresh produce.

Vertex Pharmaceuticals Incorporated (Vertex) is a biotechnology company in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. The Company is concentrating most of its drug development resources on four drug candidates: telaprevir (VX-950) for the treatment of hepatitis C virus (HCV) infection, VX-702 for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases, VX-770 for the treatment of cystic fibrosis (CF) and VX-883 for the treatment of bacterial infection. The Company also includes several drug candidates that are being developed by its collaborators. In June 2006, the Company entered into an agreement with Janssen Pharmaceutica, N.V. (Janssen), which is a Johnson & Johnson company, relating to telaprevir.

Biogen Idec Inc., is involved in the development, manufacturing and commercialization of therapies in the areas of oncology, neurology and immunology. The Company has five products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab), ZEVALIN (ibritumomab tiuxetan) and FUMADERM (dimethylfumarate and monoethylfumarate salts). In November 2006, the Company launched AVONEX in Japan, following the approval of the Japanese Ministry of Health, Labour and Welfare. On June 5, 2006, Biogen Idec Inc., and Elan Corporation plc (Elan) announced the FDA’s approval of the sBLA for the re-introduction of TYSABRI as a monotherapy treatment for relapsing forms of MS to slow the progression of disability and reduce the frequency of clinical relapses. In June 2006, the Company acquired Fumapharm AG (Fumapharm). During the year ended December 31, 2006, Biogen Idec Inc., sold all rights in AMEVIVE to Astellas Pharma US, Inc